1. Home
  2. CRON vs RAPP Comparison

CRON vs RAPP Comparison

Compare CRON & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRON
  • RAPP
  • Stock Information
  • Founded
  • CRON 2012
  • RAPP 2022
  • Country
  • CRON Canada
  • RAPP United States
  • Employees
  • CRON N/A
  • RAPP N/A
  • Industry
  • CRON Medicinal Chemicals and Botanical Products
  • RAPP
  • Sector
  • CRON Health Care
  • RAPP
  • Exchange
  • CRON Nasdaq
  • RAPP Nasdaq
  • Market Cap
  • CRON 737.8M
  • RAPP 844.6M
  • IPO Year
  • CRON N/A
  • RAPP 2024
  • Fundamental
  • Price
  • CRON $1.99
  • RAPP $12.69
  • Analyst Decision
  • CRON Hold
  • RAPP Strong Buy
  • Analyst Count
  • CRON 2
  • RAPP 4
  • Target Price
  • CRON $3.00
  • RAPP $37.33
  • AVG Volume (30 Days)
  • CRON 1.5M
  • RAPP 119.0K
  • Earning Date
  • CRON 02-27-2025
  • RAPP 02-10-2025
  • Dividend Yield
  • CRON N/A
  • RAPP N/A
  • EPS Growth
  • CRON N/A
  • RAPP N/A
  • EPS
  • CRON N/A
  • RAPP N/A
  • Revenue
  • CRON $111,229,000.00
  • RAPP N/A
  • Revenue This Year
  • CRON $40.73
  • RAPP N/A
  • Revenue Next Year
  • CRON $18.84
  • RAPP N/A
  • P/E Ratio
  • CRON N/A
  • RAPP N/A
  • Revenue Growth
  • CRON 30.31
  • RAPP N/A
  • 52 Week Low
  • CRON $1.86
  • RAPP $12.10
  • 52 Week High
  • CRON $3.14
  • RAPP $29.74
  • Technical
  • Relative Strength Index (RSI)
  • CRON 48.78
  • RAPP N/A
  • Support Level
  • CRON $1.93
  • RAPP N/A
  • Resistance Level
  • CRON $2.01
  • RAPP N/A
  • Average True Range (ATR)
  • CRON 0.07
  • RAPP 0.00
  • MACD
  • CRON 0.00
  • RAPP 0.00
  • Stochastic Oscillator
  • CRON 34.83
  • RAPP 0.00

About CRON Cronos Group Inc. Common Share

Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the US, the company has an option to acquire 5.9% of US multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.

About RAPP Rapport Therapeutics Inc. Common Stock

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Share on Social Networks: